ANTIHYPERLIPIDEMIC AND HEPATOPROTECTIVE STUDIES ON LEAVES OF MACARANGA TANARIUS

Phebe Hendra,Oktariani Aurelia Jamil,Fenty Fenty,Maria Angelika Suhadi,Dian Ayu Maharani,Jeffry Julianus,Cyndi Yulanda Putri

doi:10.22159/ajpcr.2017.v10i1.15044

Abstract

ABSTRACTObjective: This study investigated the antihyperlipidemic and hepatoprotective effects of the hexane-ethanol fraction of methanol extract ofMacaranga tanarius (HEM) in rats.Methods: The hexane-ethanol fraction was screened for toxicity by oral acute toxicity study. The antihyperlipidemic effect of the hexane-ethanolfraction and the unsolved of the hexane-ethanol fraction is measured against Wistar rats induced by glucose-fructose diets for 42 days throughmeasuring serum cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and fastingblood glucose. The hepatoprotective effect of the hexane-ethanol fraction is determined against Wistar rats with liver damage induced by carbontetrachloride through measuring serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetate transaminase (SGOT), alkalinephosphatase (ALP), albumin, lactate dehydrogenase (LDH), and total bilirubin.Results: There is no toxic effect that was observed on acute toxicity study. The TG, LDL-c, and fasting blood glucose levels were significantly (p<0.05)reduced after both of treatment the hexane-ethanol fraction and the unsolved HEM. Administration of the hexane-ethanol fraction 68.6 mg/kgBWsignificantly (p<0.05) prevented elevation of SGPT, SGOT, LDH, ALP, and decreasing of albumin level.Conclusion: The study showed antihyperlipidemic and hepatoprotective activities of the HEM in animal models.Keywords: Macaranga tanarius, Antihyperlipidemic, Hepatoprotective.

Highlights

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning of the hepatocytes
Metabolic comorbidities associated with NAFDL included obesity, type 2 diabetes, hyperlipidemia, hypertension, and metabolic syndrome
Diagnostic kit for the estimation of serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetate transaminase (SGOT), alkaline phosphatase (ALP), albumin, lactate dehydrogenase (LDH), total bilirubin, glucose, cholesterol, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and triglyceride (TG) kits were purchased were from Roche Diagnostics GmbH, Mannheim, Germany

Summary

Introduction

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning of the hepatocytes. NAFDL is associated with metabolic risk factors such as obesity, diabetes mellitus, and dyslipidemia [1]. Metabolic comorbidities associated with NAFDL included obesity, type 2 diabetes, hyperlipidemia, hypertension, and metabolic syndrome. As the global epidemic continues to fuel development of metabolic disorders, NAFDL will create a massive clinical and economic burden [2]. Carbon tetrachloride (CCL4) is one of the most commonly hepatotoxic agents that have been reported to show steatosis, centrilobular necrosis, inflammation, fibrosis, and liver cancer in the experimental animals [3,4]. Administration of high carbohydrate diet in animal models is frequently induced obesity, insulin resistance, impaired glucose tolerance, hyperinsulinemia, hypertension, and hyperlipidemia [5,6,7,8,9,10]

Methods

Results

Conclusion